Morgan Stanley reissued their equal weight rating on shares of Cytokinetics (NASDAQ:CYTK – Free Report) in a research note published on Friday morning, MarketBeat.com reports. They currently have a $90.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $60.00. A number of other analysts have also issued reports on […]
StockNews.com downgraded shares of Cytokinetics (NASDAQ:CYTK – Free Report) from a hold rating to a sell rating in a research report sent to investors on Friday morning. Several other equities analysts also recently issued reports on CYTK. The Goldman Sachs Group started coverage on Cytokinetics in a research report on Thursday, November 9th. They set […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its price objective raised by Truist Financial from $60.00 to $86.00 in a report released on Thursday morning, Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. Several other research firms have also commented on CYTK. Cantor Fitzgerald boosted their price objective on Cytokinetics from […]
Cytokinetics (NASDAQ:CYTK – Free Report) had its target price lifted by HC Wainwright from $58.00 to $94.00 in a report released on Wednesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the biopharmaceutical company’s stock. Several other equities research analysts have also issued reports on the company. The Goldman Sachs Group began […]
Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) was the target of some unusual options trading on Thursday. Stock investors acquired 36,208 call options on the company. This is an increase of 350% compared to the average volume of 8,049 call options. Insider Activity at Cytokinetics In related news, CEO Robert I. Blum sold 12,500 shares […]